Sanofi: high-dose Fluzone vaccine approved
(CercleFinance.com) - Sanofi has announced that the US FDA has a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older.
This version will be available for the immunization efforts during the 2020-2021 flu vaccination campaign. Sanofi Pasteur will continue to produce and distribute the trivalent version until the end of the 2019-2020 flu season.
At the end of the 2018-2019 season, over 112 million doses of high-dose Fluzone had been distributed to the United States. During the season, nearly two thirds of the over-65s vaccinated against flu in the US received high-dose Fluzone.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This version will be available for the immunization efforts during the 2020-2021 flu vaccination campaign. Sanofi Pasteur will continue to produce and distribute the trivalent version until the end of the 2019-2020 flu season.
At the end of the 2018-2019 season, over 112 million doses of high-dose Fluzone had been distributed to the United States. During the season, nearly two thirds of the over-65s vaccinated against flu in the US received high-dose Fluzone.
Copyright (c) 2019 CercleFinance.com. All rights reserved.